Vascular Contributions to Alzheimer Disease and Mixed Pathology
📖 Wiki Page
experiment635 wordssynced 2026-04-02
Rank: 52 (from experiment-priority-index.md)
Key Question
How does vascular dysfunction interact with amyloid and tau pathology in mixed dementia, and can addressing vascular health enhance anti-amyloid therapeutic efficacy?
Background
Vascular dementia (VaD) and Alzheimer's disease (AD) frequently co-occur as mixed pathology. The vascular contributions to AD hypothesis proposes that cerebral small vessel disease (CSVD), white matter hyperintensities, and microinfarcts contribute to cognitive decline independently of and synergistically with amyloid and tau pathology. Understanding this interaction is critical for the ~30-50% of AD patients who have significant vascular comorbidity.
Hypothesis
Vascular dysfunction (BBB breakdown, hypoperfusion, white matter lesions) acts as an independent driver of cognitive decline and accelerates amyloid/tau pathology through multiple mechanisms. Combined vascular + anti-amyloid therapy will show greater efficacy than either alone.
Validation Protocol
Study Design: Multi-Cohort Imaging and Biomarker Study
Cohort 1: Pure AD (n=100)
Amyloid PET positive, minimal vascular burden (Fazekas 0-1)
Amyloid PET positive with significant vascular burden (Fazekas 2-3 or prior lacunes)
Matched to Cohort 1 for age, education, amyloid burden
Same baseline and follow-up protocol
...
Rank: 52 (from experiment-priority-index.md)
Key Question
How does vascular dysfunction interact with amyloid and tau pathology in mixed dementia, and can addressing vascular health enhance anti-amyloid therapeutic efficacy?
Background
Vascular dementia (VaD) and Alzheimer's disease (AD) frequently co-occur as mixed pathology. The vascular contributions to AD hypothesis proposes that cerebral small vessel disease (CSVD), white matter hyperintensities, and microinfarcts contribute to cognitive decline independently of and synergistically with amyloid and tau pathology. Understanding this interaction is critical for the ~30-50% of AD patients who have significant vascular comorbidity.
Hypothesis
Vascular dysfunction (BBB breakdown, hypoperfusion, white matter lesions) acts as an independent driver of cognitive decline and accelerates amyloid/tau pathology through multiple mechanisms. Combined vascular + anti-amyloid therapy will show greater efficacy than either alone.
Validation Protocol
Study Design: Multi-Cohort Imaging and Biomarker Study
Cohort 1: Pure AD (n=100)
Amyloid PET positive, minimal vascular burden (Fazekas 0-1)